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Summary
Familial eosinophilia (FE) is an autosomal dominant dis-
order characterized by peripheral hypereosinophilia of
unidentifiable cause with or without other organ in-
volvement. To localize the gene for FE, we performed a
genomewide search in a large U.S. kindred, using 312
different polymorphic markers. Seventeen affected sub-
jects, 28 unaffected bloodline relatives, and 8 spouses
were genotyped. The initial linkage results from the
genome scan provided evidence for linkage on chro-
mosome 5q31-q33. Additional genotyping of genetic
markers located in this specific region demonstrated sig-
nificant evidence that the FE locus is situated between
the chromosome 5q markers D5S642 and D5S816 (mul-
tipoint LOD score of 6.49). Notably, this region
contains the cytokine gene cluster, which includes
three genes—namely, those for interleukin (IL)–3, IL-5,
and granulocyte/macrophage colony-stimulating factor
(GM-CSF)—whose products play important roles in the
development and proliferation of eosinophils. These
three cytokine genes were screened for potential disease-
specific mutations by resequencing of a subgroup of in-
dividuals from the present kindred. No functional se-
quence polymorphisms were found within the promoter,
the exons, or the introns of any of these genes or within
the IL-3/GM-CSF enhancer, suggesting that the primary
defect in FE is not caused by a mutation in any one of
these genes but, rather, is caused by another gene in the
area.
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Introduction
Eosinophilia, defined as 1500 eosinophils/ml blood, often
is associated with infectious (e.g., tissue-invasive hel-
minths), allergic (e.g., asthma), myeloproliferative (e.g.,
various lymphomas and leukemias), connective-tissue
(e.g., rheumatoid arthritis), and gastrointestinal (e.g.,
gastroenteritis) diseases. The most dramatic increases in
eosinophils occur in idiopathic hypereosinophilic syn-
dromes (HESs), which encompass a spectrum of disor-
ders, including Loeffler syndrome, Loeffler endocarditis,
and eosinophilic leukemia. Hardy and Anderson (1968)
suggested that these disorders, which have marked eo-
sinophilia and organ dysfunction, could be grouped to-
gether as HES. HES is characterized by (1) persistent
eosinophilia ( eosinophils/liter) for at least91 1.5# 10
6 mo; (2) no evidence of parasitic, allergic, or other
recognized causes of eosinophilia, after comprehensive
evaluation; and (3) signs and symptoms of organ dys-
function that can be directly related to eosinophilia or
that otherwise are unexplained in the clinical setting
(Chusid et al. 1975; Parrillo et al. 1978; Fauci et al.
1982).
Familial eosinophilia (FE; MIM 131400), although
rare, has been well documented since the early 1900s
(Gaugain 1909; Naiman et al. 1964). FE composes a
subset of HES and is transmitted in an autosomal dom-
inant pattern. To determine the molecular basis of FE,
we undertook a genomewide linkage approach to the
study of a five-generation kindred with documented FE
(Lin et al. 1998). The genotyping of 17 affected subjects,
28 unaffected bloodline relatives, and 8 spouses, with
312 highly polymorphic genetic markers, revealed a sin-
gle locus of interest on chromosome 5q31-q33. The hu-
man cytokine gene cluster has been localized to this re-
gion and contains the genes for interleukin (IL)–3, IL-5,
and granulocyte/macrophage colony-stimulating factor
(GM-CSF). Since these three cytokines have been shown
to activate eosinophils in vitro (Owen et al. 1987; Roth-
enberg et al. 1988, 1989), the genes encoding them were
considered as candidates for the FE locus. Resequencing
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of these three genes in five affected and three unaffected
individuals from this kindred did not reveal any poten-
tially disease-causing mutations.
Subjects and Methods
Family
The family was referred to the National Institutes of
Health by Dr. P. K. Raghuprasad for the study of HES
in the proband. Further investigation revealed multiple
affected family members. Informed consent was ob-
tained prior to participation in the clinical and/or lab-
oratory evaluations, under an institutional review
board–approved clinical study protocol. Age at exami-
nation varied as follows: 12–70 years for affected in-
dividuals, !1–65 years for unaffected family members,
and 33–91 years for spouses. Fifty-three individuals
from this kindred had a complete blood count docu-
menting their eosinophil counts. Of them, 17 subjects
were affected, and 36 individuals were unaffected. For
the purpose of this study, FE was defined by the presence
of eosinophilia—that is, eosinophils/li-91 1.5 # 10
ter—without detectable causes. Twenty-three family
members also underwent a clinical evaluation at the Na-
tional Institutes of Health, under an approved clinical
study protocol. Clinical examination included routine
physical evaluation and examination of stool ova and
parasites, echocardiogram evaluation, and cytogenetic
study. The other 30 family members were evaluated dur-
ing field trips that included phlebotomy and a complete
blood count.
Genotyping
Genomic DNA from peripheral blood lymphocytes
obtained from 53 family members—including 17 af-
fected individuals, 28 unaffected bloodline relatives, and
8 spouses—was used for genetic analysis. Genotyping
was performed by use of a modified version of the Co-
operative Human Linkage Center (CHLC) Human
Screening Set/version 6.0 panel of polymorphic markers
(Dubovsky et al. 1995). Specifically, the screening set
comprised 312 fluorescently labeled genetic markers
(Research Genetics) with average heterozygosity of .75
and average spacing between markers of 12 cM. Sub-
sequent to the linkage analysis of the results obtained
by means of the screening set, additional markers were
typed in order to increase the marker density in the re-
gion of chromosome 5q.
PCR reactions were set up with a robotic pipetting
station (Rosys Robotic Systems) in thin-walled 192-well
polycarbonate plates (Corning Costar). Reactions were
overlaid with light mineral oil (Sigma Chemical) and
were amplified on custom-built thermocyclers (Intelli-
gent Automation Systems), each accommodating 16
192-well plates. PCR products then were multiplexed
into panels by pooling (average of eight markers/panel)
on the basis of allele-size range and fluorescent label.
Aliquots of the multiplexed samples were mixed with
either Tamra-labeled GENESCAN 500 and GENE-
SCAN 2500 (Perkin Elmer Applied Biosystems) or rho-
damine-labeled MapMarkers (Bioventures) and then
were run on ABI377 sequencers (Perkin Elmer Applied
Biosystems).
Fluorescent genotyping gels were analyzed in an au-
tomated system developed at the Whitehead Institute/
MIT Center for Genome Research. The gels were tracked
automatically and reviewed manually by use of the Bass/
Grace gel-analysis system. Alleles were called automat-
ically by use of software (M.J.D., unpublished data) that
implements strict guidelines (to prevent miscalls due to
leakage, mistracking, weak signal, or detector satura-
tion) and that identifies alleles on the basis of their char-
acteristic response (including A and stutter bands).
Sizes were determined automatically by comparisonwith
the size standards loaded on every lane. Control geno-
types were included on every gel, to ensure accuracy and
reproducibility of allele calling. Gels, pedigrees, and
markers with aberrantly large numbers of Mendelian-
inheritance errors were reexamined carefully, to monitor
any systematic laboratory or sample mix-ups and to en-
sure that each fluorescent marker was producing a con-
sistent assay. The automated genotyping system also was
monitored frequently by comparison with manual ge-
notype calls, to ensure consistent performance.
Linkage Analysis
An initial genomewide linkage analysis was conducted
by use of the nonparametric approach implemented in
the computer program GENEHUNTER (Kruglyak et al.
1996). Because of computational constraints, the pedi-
gree was subdivided into two parts that together in-
cluded all affected individuals. The order of and the sex-
averaged distance between the markers in the screening
set were based on the published CHLC map (Murray et
al. 1994).
In a second phase, two-point linkage analysis of the
data from the higher-density mapping of chromosome
5 was performed by use of the MLINK routine of the
LINKAGE package (Lathrop et al. 1984). This para-
metric analysis was performed for the complete pedigree.
Because of the clear pattern of inheritance based on the
pedigree, a single model of a dominant, highly penetrant
trait was used. The disease gene frequency was assigned
a value of .0001. The penetrance values used were .0,
.9, and 1.0; incomplete penetrance was specified, since
individual IV-8 did not maintain hypereosinophilic
status at follow-up (Lin et al. 1998). No new mutations
were allowed, and a sex difference was not specified.
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Figure 1 Pedigree used for linkage analysis. Affected individuals are indicated by blackened symbols.
Marker allele frequencies were calculated on the basis
of the alleles observed in the founder individuals. Mul-
tipoint analysis was performed by use of the VITESSE
algorithm (O’Connell and Weeks 1995). The order of
and the sex-averaged distance between the markers in
this denser set were based on integrated maps from the
Marshfield Medical Research Foundation. Haplotypes
were reconstructed from the genotype data, by use of
the GENEHUNTER program (Kruglyak et al. 1996).
Mutation Screening
Screening for germ-line mutations in the IL-3, IL-5,
and GM-CSF genes was performed by the resequencing
of these genes in five affected individuals (IV-6, IV-12,
IV-17, V-3, and V-7) and three unaffected individuals
(IV-5, IV-14, and IV-18). Regions in which sequence
polymorphisms were detected were resequenced in the
remaining affected individuals and in an additional 10
unaffected individuals.
The resequencing was performed by PCR amplifica-
tion of genomic DNA, by use of overlapping primer pairs
covering the exons, introns, and 5′ UTR of each gene.
The PCR products were purified by use of the solid-
phase reversible immobilization technique (Hawkins et
al. 1994), and both strands were sequenced by use of
FS dye primer cycle-sequencing kits (Perkin Elmer Ap-
plied Biosystems) and then were run on ABI377 se-
quencers. The sequences obtained were aligned by use
of the Staden (GAP4) package (Staden 1996). The ref-
erence genomic sequence for the IL-3 and IL-5 genes
was obtained from the Lawrence Berkeley National Lab-
oratory, Human Genome Center. The reference genomic
sequence for the GM-CSF gene was taken from the pub-
lished sequence (Miyatake et al. 1985 [Entrez accession
number X03021]). The enhancer region for the IL-3/
GM-CSF proximal promoters also was sequenced (nu-
cleotides 42–689 [Entrez accession number L07488]).
Results
Family study
Figure 1 shows the pedigree for the family members
used in this genomewide linkage study. The family in-
cludes 24 affected individuals (19 were studied), over
five generations, and has been described elsewhere (Lin
et al. 1998). Cardiac abnormalities were diagnosed in
five subjects (III-3, II-11, III-14, IV-6, and IV-12) with
sustained eosinophilia, of whom two (III-14 and IV-12)
had neurological symptoms (Lin et al. 1998). There was
no evidence of parasitic, allergic, or other recognized
causes of eosinophilia. A previous study of these family
members demonstrated that the serum quantities of three
important eosinophilopoietic cytokines were either un-
detectable (IL-3 and GM-CSF) or not significantly dif-
ferent (IL-5) in our FE patients, as compared with the
quantities that were measurable in control individuals
(Lin et al. 1998).
Linkage Analysis
Nonparametric analysis of the data from the ge-
nomewide screen was performed initially so that the
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Figure 2 Linkage map of the chromosome 5q region of interest.
Markers included in the initial genomewide screen (underlined) and
the additional markers used to increase marker density are shown,
with the estimated distance between loci indicated in centimorgans.
“X” indicates the recombinants that define a maximum interval be-
tween markers D6S642 and D5S1480 (vertical arrowheads). The hor-
izontal arrow indicates the most likely position for the FE gene, based
on the four-point linkage analysis using the genotype data from mark-
ers D5S1505, D5S642, and D5S816.
Table 1
Two-Point LOD Scores between Chromosome 5q Markers and the
Disease Locus
LOCUS
LOD SCORE AT RECOMBINATION FRACTION OF
.000 .010 .050 .100 .200 .300 .400
D5S1468 2.15 1.05 .12 0.46 .54 0.36 .13
D5S1505 4.00 2.17 3.16 3.28 2.81 1.96 .93
D5S642 1.12 1.74 2.08 2.02 1.58 1.01 .45
D5S816 1.63 1.69 1.76 1.69 1.31 0.82 .32
D5S399 4.88 1.75 .49 0.03 .16 0.09 .03
D5S1480 5.05 1.71 .48 0.02 .24 0.22 .11
linkage analysis would be independent of mode-of-dis-
ease inheritance and penetrance values. This linkage
analysis gave a single peak for chromosome 5, centered
at marker D5S1505 (nonparametic linkage score, 2.12;
P value, .0097). No other chromosome showed evidence
of excess sharing (data not shown).
In a second phase, additional markers on chromosome
5q were genotyped, and the data were combined with
those from the initial genomewide screen. Two-point
maximum-likelihood calculations based on this com-
bined data set yielded a parametric LOD score of 3.28,
between D5S1505 and the disease locus. Table 1 sum-
marizes the two-point LOD scores between chromosome
5q markers and the FE disease locus. To extract more
information from this genotype data, four-point linkage
analyses were performed by use of the VITESSE algo-
rithm, for markers located between D5S1468 and
D5S399. The maximum multipoint LOD score (6.49)
was obtained when markers D5S1505, D5S642, and
D5S816 were examined, with the disease locus placed
between the latter two markers (fig. 2). Analysis of re-
constructed haplotypes for the 5q region indicated the
presence of obligate recombinants that defined a max-
imum interval, of 18 cM, between markers D5S642 and
D5S1480 (fig. 2).
Candidate-Gene Analysis
We screened the IL-3, IL-5, and GM-CSF genes for
mutations, because they are three known regulators of
eosinophil differentiation and proliferation and because
they map to the critical interval. For the initial screen,
genomic sequences were obtained for five affected in-
dividuals and three spouses from this pedigree. Specifi-
cally, the genomic regions from 1860 to 2569, from
925 to 2385, and from 599 to 2043, for the IL-3,
IL-5, and GM-CSF genes, respectively, were studied (po-
sition 0 refers to the first nucleotide of exon 1). As sum-
marized schematically in figure 3, the entire sequence for
all exons and introns was obtained, except for 170 bp
of the second intron of IL-3, 70 bp of the second intron
of IL-5, and 610 bp of the third intron of GM-CSF. The
upstream regions that were sequenced contained all the
known promoter elements for the IL-3 (Engeland et al.
1995; Nimer et al. 1996; Taylor et al. 1996), IL-5
(Gruart-Gouilleux et al. 1995; Yamagata et al. 1995;
Karlen et al. 1996a, 1996b; Stranick et al. 1997), and
GM-CSF (Cousins et al. 1994;Wang et al. 1994; Staynov
et al. 1995; Cockerill et al. 1996) genes. In addition, the
inducible enhancer for the IL-3 and GM-CSF gene pro-
moters (Cockerill et al. 1993), located in the 10-kb
region that separates these two genes, also was rese-
quenced. The sequences of all eight individuals were
identical at all but three positions in the 110 kb ex-
amined, as summarized in table 2. These three differ-
ences, all single-nucleotide polymorphisms, were ex-
amined in an additional 22 members of this pedigree,
for a total of 17 affected and 13 unaffected individuals
examined. A common haplotype (CAG) was seen in all
17 affected and in only 2 of the 13 unaffected individuals
examined. Finally, none of these polymorphisms ap-
peared to be a functional mutation: the polymorphism
found in the IL-5 promoter region is not located in any
of the known regulatory elements, the one located in the
IL-5 coding region is a silent substitution, and the one
located in the IL-3/GM-CSF enhancer is not within the
known transcription-factor binding sites. Moreover, all
Figure 3 Schematic diagram of three candidate genes examined for mutations. A, Genomic organization of three candidate genes. The
orientation of each gene is represented by the direction of the arrows, and the distances between the three cytokine genes and the IL-3/GM-
CSF enhancer (“ENH”) are indicated below the horizontal line. B–D, Genomic structure of and PCR products sequenced for the IL-5 (B), GM-
CSF (C), and IL-3 (D) genes. In each panel, the top line includes shaded boxes that represent exons, vertical bars that represent sequence
position relative to the first nucleotide of exon 1, and vertical arrows that represent the location of the sequence polymorphisms detected. The
PCR products that were sequenced are shown as small horizontal bars and are numbered sequentially. E, Genomic structure of the IL-3/GM-
CSF inducible enhancer. The blackened squares represent the essential transcription-factor binding sites characterized elsewhere (Cockerill et
al. 1993, 1996), and the vertical arrow indicates the location of the sequence polymorphism detected. The nucleotide positions given are taken
from reference (Cockerill et al. 1993).
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Table 2
Summary of the Sequence Polymorphisms Detected in the IL-3,
IL-5, and GM-CSF Genes
Gene Location Polymorphism
Nucleotide
Position
IL-5 5′ UTR C or T 703a
IL-5 Exon 1 CG(A or G) 168a
IL-3/GM-CSF Enhancer G or T 240b
a Relative to the first nucleotide of exon 1.
b Relative to the published sequence (Cockerhill et al. 1993).
three of the alleles found in the shared affected haplotype
also were observed in unaffected individuals.
Discussion
We report the results of a genomewide linkage analysis
of a large kindred with an autosomal dominant form of
FE. The initial results from the genomewide scan pro-
vided evidence that the FE locus is situated in the 5q31-
q33 region. Subsequent mapping using a higher density
of markers further supported the evidence that this re-
gion is the location of the FE gene, with a maximum
two-point LOD score of 3.28, at recombination fraction
.1, for the D5S1505 locus and a maximum multipoint
LOD score of 6.49 for the 6-cM region between loci
D5S642 and D5S816. This was supported further by
analysis of the reconstructed haplotypes, which indi-
cated a critical region delimited by markers D5S642 and
D5S1480.
The results of most karyotype analyses for HES have
been reported to be normal. However, previous karyo-
type analysis of affected individuals from this kindred
revealed a pericentric-centric inversion of chromosome
10, inv(10)(p11.2q21.2), in two individuals (III-14 and
IV-29) (Lin et al. 1998). The observation of genetic link-
age to 5q31-q33 suggests that the latter chromosomal
variation is unrelated to HES. Linkage to the 5q31-q33
region may be supported further by several reports of
chromosomal abnormalities involving 5q31-q33 in pa-
tients with eosinophilia associated with malignancies,
such as chronic myelomonocytic leukemia, acute lym-
phocytic leukemia, and myelodysplastic or myeloproli-
ferative syndromes (Hogan et al. 1987; Baumgarten et
al. 1989; Berkowicz et al. 1991; Yates and Potter 1991;
Baranger et al. 1994; Jani et al. 1994; Matsushima et
al. 1994). This also may suggest that the FE gene, or
another gene located in 5q31-q33, potentially could play
a role in the eosinophilia associated with these neoplastic
syndromes. However, the recurrence of translocations in
this region may be unrelated to the eosinophilia, per se,
since other groups have reported different translocation
events in tumor cells related to eosinophilic paraneo-
plastic syndromes (Goh et al. 1985; Matsushima et al.
1994).
The fact that FE maps to 5q31-q33 is particularly
interesting in view of the fact that genes encoding IL-3,
IL-5, and GM-CSF, three well-described cytokines that
play an important role in the differentiation and prolif-
eration of eosinophils (reviewed in Weller 1991), map
to this region. A role for these three cytokines in the
control of eosinophilic proliferation is supported by the
presence of specific cell-surface receptors on eosinophils
(Lopez et al. 1989; Chihara et al. 1990) and by studies
demonstrating the in vitro activation of normal eosino-
phils in the presence of any one of these immunoreg-
ulatory molecules (Owen et al. 1987; Rothenberg et al.
1987, 1989). Moreover, the serum from some patients
with idiopathic eosinophilia has been shown to contain
a factor that increases the viability of eosinophils in vi-
tro. This activity was abrogated on the addition of
anti–IL-5 but not on the addition of either anti–IL-3 or
anti–GM-CSF (Owen et al. 1989). This indicates that
IL-5 plays an important role in maintaining the viability
of eosinophils in culture.
A prominent role for IL-5 in the control of eosinophil
differentiation and proliferation in vivo also has been
suggested strongly by the study of transgenic mouse
models of eosinophilia. These studies demonstrated that
eosinophilia resulted when the murine IL-5 gene was
uncoupled from its endogenous transcriptional control
mechanisms (Dent et al. 1990; Vaux et al. 1990; Schre-
zenmeier et al. 1993; Lee et al. 1997). In two of these
studies the eosinophilia was not accompanied by any
detectable histopathology (Dent et al. 1990; Vaux et al.
1990), suggesting that the induction of the IL-5 gene
was sufficient for producing eosinophilia but that the
expression pattern of the IL-5 gene was likely to be im-
portant in the determination of whether any histopa-
thology would result (Lee et al. 1997). The control of
eosinophil differentiation and proliferation may not be
restricted to IL-5, however, since similar activity has been
proposed for the IL-3 and GM-CSF genes, following in
vitro studies using cells from patients with either idio-
pathic eosinophilia or eosinophilia as a paraneoplastic
syndrome (Sanderson 1992; Fremand et al. 1993; Schre-
zenmeier et al. 1993).
Because the eosinophilia in the present kindred seg-
regates as a dominant phenotype, a disease-causing mu-
tation in one of the three cytokines studied might be
expected to result in a gain of function or in an increase
in gene expression; although less likely, the null mutation
could result in haploinsufficiency. Since the only poly-
morphism found in the coding sequences for the IL-3,
IL-5, and GM-CSF genes was silent (table 2) and thus
was unable to affect the function of its product, the
region upstream of the first exon of each gene was ex-
amined for mutations that possibly could affect gene
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regulation. The only polymorphism in the proximal pro-
moter regions, found upstream of the IL-5 gene, was not
located within any of the known cis-acting elements and
thus is unlikely to affect gene expression. Likewise, the
polymorphism located within the IL-3/GM-CSF induc-
ible enhancer does not colocalize to any of the previously
defined transcription-factor binding sites. Although we
did not test directly whether the latter two polymor-
phisms affected gene expression, these sites are unlikely
to represent novel regulatory sites, since the promoter
regions of these three genes have been studied extensively
by a number of groups and have not shown any evidence
of regulatory elements in the regions where the poly-
morphisms were found (Cockerill et al. 1993, 1996;
Cousins et al. 1994; Wang et al. 1994; Engeland et al.
1995; Gruart-Gouilleux et al. 1995; Staynov et al. 1995;
Yamagata et al. 1995; Karlen et al. 1996a, 1996b;Nimer
et al. 1996; Taylor et al. 1996; Stranick et al. 1997).
More importantly, these polymorphisms also were de-
tected both in unaffected relatives and in spouses. It
therefore seems unlikely that one of these three cytokines
represents the FE gene.
Although abnormally high quantities of IL-5 in the
blood of humans and mice have been suggested to ac-
count for the histopathology observed for eosinophilia
(Owen et al. 1989; Lee et al. 1997), causality is difficult
to establish, since activated eosinophils have the ability
to produce IL-3, IL-5, and GM-CSF (Kita et al. 1991;
Moqbel et al. 1991; Broide et al. 1992; Desreumaux et
al. 1992, 1993). Moreover, since the serum quantities
of these three cytokines in our FE patients were either
undetectable (IL-3 and GM-CSF) or not significantly dif-
ferent from the quantities that were measurable in con-
trol individuals (IL-5) (Lin et al. 1998), high systemic
levels of these molecules do not appear to be necessary
for pathology. However, an intracellular interaction of
the cytokines with their receptors within eosinophils or
a close intercellular interaction between T lymphocytes
and eosinophils possibly could explain the activity of
these factors, even under conditions of undetectable se-
rum concentrations.
In summary, we present strong evidence that the FE
locus is located in the 5q31-q33 region. Since there are
1100 anonymous transcripts in this region of interest
(Schuler et al. 1996), the FE gene may be a novel gene.
The FE gene may represent a novel eosinophil growth
factor, or it could be a regulator of transcription of the
known eosinophilopoietins. In any case, the identity of
the FE gene will be important to elucidate, in order to
gain a better understanding of the control of eosinophil
proliferation and differentiation and of the mechanisms
responsible for the pathology observed in idiopathic eo-
sinophilia as well as in eosinophilia related to atopy and
malignancy.
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